A novel probiotic therapeutic in a murine model of Clostridioides difficile colitis

Clostridioides difficile infection (CDI) is a common cause of antimicrobial-associated diarrhea. Probiotics have shown variable results in decreasing its incidence and severity. We examined the efficacy of Lactobacillus reuteri administered using a novel probiotic biofilm delivery system in the trea...

Full description

Bibliographic Details
Main Authors: Rita D. Shelby, Grace E. Janzow, Lauren Mashburn-Warren, Jeffrey Galley, Natalie Tengberg, Jason Navarro, Miriam Conces, Michael T. Bailey, Steven D. Goodman, Gail E. Besner
Format: Article
Language:English
Published: Taylor & Francis Group 2020-11-01
Series:Gut Microbes
Subjects:
Online Access:http://dx.doi.org/10.1080/19490976.2020.1814119
id doaj-5b1c648885f44f94a5e67e10be033c35
record_format Article
spelling doaj-5b1c648885f44f94a5e67e10be033c352021-03-18T15:12:50ZengTaylor & Francis GroupGut Microbes1949-09761949-09842020-11-0112110.1080/19490976.2020.18141191814119A novel probiotic therapeutic in a murine model of Clostridioides difficile colitisRita D. Shelby0Grace E. Janzow1Lauren Mashburn-Warren2Jeffrey Galley3Natalie Tengberg4Jason Navarro5Miriam Conces6Michael T. Bailey7Steven D. Goodman8Gail E. Besner9Nationwide Children’s HospitalNationwide Children’s HospitalThe Research Institute at Nationwide Children’s HospitalNationwide Children’s HospitalNationwide Children’s HospitalNationwide Children’s HospitalNationwide Children’s HospitalThe Research Institute at Nationwide Children’s HospitalThe Research Institute at Nationwide Children’s HospitalNationwide Children’s HospitalClostridioides difficile infection (CDI) is a common cause of antimicrobial-associated diarrhea. Probiotics have shown variable results in decreasing its incidence and severity. We examined the efficacy of Lactobacillus reuteri administered using a novel probiotic biofilm delivery system in the treatment and prevention of CDI in a murine model. For prophylactic therapy, mice received an oral antibiotic cocktail followed by clindamycin injection, followed by probiotic administration (planktonic vs. biofilm state), followed by C. difficile oral gavage. For treatment therapy, mice received antibiotics and C. difficile first, followed by probiotic administration. Clinical sickness scores (CSS) and intestinal histologic injury scores (HIS) were assigned. In the Prophylactic Therapy model, CSS: 67% of untreated mice exposed to C. difficile demonstrated CSS ≥ 6, which is consistent with C. difficile infection (p< .001 compared to unexposed mice). In mice treated with planktonic Lr, 55% had a CSS ≥ 6, but only 19% of mice treated with Lr in its biofilm state had CSS ≥ 6 (p< .001). Mice receiving Lr + DM-Maltose lost the least amount of weight compared to mice receiving saline (p = .004676) or to mice receiving Lr (p= .003185). HIS: 77% of untreated mice exposed to C. difficile had HIS scores ≥4, which is consistent with C. difficile infection. In mice treated with planktonic Lr, 62% had HIS ≥4, but only 19% of mice treated with Lr in its biofilm state had HIS ≥4. (p< .001). Additionally, mice treated with Lr in its biofilm state had better survival compared to untreated mice and to mice treated with planktonic Lr (p ≤ 0.05). Similar findings for weight loss, CSS, HIS and survival were obtained for Treatment Therapy. A single dose of Lactobacillus reuteri in its biofilm state reduces the severity and incidence of experimental C. difficile infection when administered as both prophylactic and treatment therapy.http://dx.doi.org/10.1080/19490976.2020.1814119c. difficileprobioticslactobacillus reuteribiofilmtherapeutic treatmentprophylactic treatment
collection DOAJ
language English
format Article
sources DOAJ
author Rita D. Shelby
Grace E. Janzow
Lauren Mashburn-Warren
Jeffrey Galley
Natalie Tengberg
Jason Navarro
Miriam Conces
Michael T. Bailey
Steven D. Goodman
Gail E. Besner
spellingShingle Rita D. Shelby
Grace E. Janzow
Lauren Mashburn-Warren
Jeffrey Galley
Natalie Tengberg
Jason Navarro
Miriam Conces
Michael T. Bailey
Steven D. Goodman
Gail E. Besner
A novel probiotic therapeutic in a murine model of Clostridioides difficile colitis
Gut Microbes
c. difficile
probiotics
lactobacillus reuteri
biofilm
therapeutic treatment
prophylactic treatment
author_facet Rita D. Shelby
Grace E. Janzow
Lauren Mashburn-Warren
Jeffrey Galley
Natalie Tengberg
Jason Navarro
Miriam Conces
Michael T. Bailey
Steven D. Goodman
Gail E. Besner
author_sort Rita D. Shelby
title A novel probiotic therapeutic in a murine model of Clostridioides difficile colitis
title_short A novel probiotic therapeutic in a murine model of Clostridioides difficile colitis
title_full A novel probiotic therapeutic in a murine model of Clostridioides difficile colitis
title_fullStr A novel probiotic therapeutic in a murine model of Clostridioides difficile colitis
title_full_unstemmed A novel probiotic therapeutic in a murine model of Clostridioides difficile colitis
title_sort novel probiotic therapeutic in a murine model of clostridioides difficile colitis
publisher Taylor & Francis Group
series Gut Microbes
issn 1949-0976
1949-0984
publishDate 2020-11-01
description Clostridioides difficile infection (CDI) is a common cause of antimicrobial-associated diarrhea. Probiotics have shown variable results in decreasing its incidence and severity. We examined the efficacy of Lactobacillus reuteri administered using a novel probiotic biofilm delivery system in the treatment and prevention of CDI in a murine model. For prophylactic therapy, mice received an oral antibiotic cocktail followed by clindamycin injection, followed by probiotic administration (planktonic vs. biofilm state), followed by C. difficile oral gavage. For treatment therapy, mice received antibiotics and C. difficile first, followed by probiotic administration. Clinical sickness scores (CSS) and intestinal histologic injury scores (HIS) were assigned. In the Prophylactic Therapy model, CSS: 67% of untreated mice exposed to C. difficile demonstrated CSS ≥ 6, which is consistent with C. difficile infection (p< .001 compared to unexposed mice). In mice treated with planktonic Lr, 55% had a CSS ≥ 6, but only 19% of mice treated with Lr in its biofilm state had CSS ≥ 6 (p< .001). Mice receiving Lr + DM-Maltose lost the least amount of weight compared to mice receiving saline (p = .004676) or to mice receiving Lr (p= .003185). HIS: 77% of untreated mice exposed to C. difficile had HIS scores ≥4, which is consistent with C. difficile infection. In mice treated with planktonic Lr, 62% had HIS ≥4, but only 19% of mice treated with Lr in its biofilm state had HIS ≥4. (p< .001). Additionally, mice treated with Lr in its biofilm state had better survival compared to untreated mice and to mice treated with planktonic Lr (p ≤ 0.05). Similar findings for weight loss, CSS, HIS and survival were obtained for Treatment Therapy. A single dose of Lactobacillus reuteri in its biofilm state reduces the severity and incidence of experimental C. difficile infection when administered as both prophylactic and treatment therapy.
topic c. difficile
probiotics
lactobacillus reuteri
biofilm
therapeutic treatment
prophylactic treatment
url http://dx.doi.org/10.1080/19490976.2020.1814119
work_keys_str_mv AT ritadshelby anovelprobiotictherapeuticinamurinemodelofclostridioidesdifficilecolitis
AT graceejanzow anovelprobiotictherapeuticinamurinemodelofclostridioidesdifficilecolitis
AT laurenmashburnwarren anovelprobiotictherapeuticinamurinemodelofclostridioidesdifficilecolitis
AT jeffreygalley anovelprobiotictherapeuticinamurinemodelofclostridioidesdifficilecolitis
AT natalietengberg anovelprobiotictherapeuticinamurinemodelofclostridioidesdifficilecolitis
AT jasonnavarro anovelprobiotictherapeuticinamurinemodelofclostridioidesdifficilecolitis
AT miriamconces anovelprobiotictherapeuticinamurinemodelofclostridioidesdifficilecolitis
AT michaeltbailey anovelprobiotictherapeuticinamurinemodelofclostridioidesdifficilecolitis
AT stevendgoodman anovelprobiotictherapeuticinamurinemodelofclostridioidesdifficilecolitis
AT gailebesner anovelprobiotictherapeuticinamurinemodelofclostridioidesdifficilecolitis
AT ritadshelby novelprobiotictherapeuticinamurinemodelofclostridioidesdifficilecolitis
AT graceejanzow novelprobiotictherapeuticinamurinemodelofclostridioidesdifficilecolitis
AT laurenmashburnwarren novelprobiotictherapeuticinamurinemodelofclostridioidesdifficilecolitis
AT jeffreygalley novelprobiotictherapeuticinamurinemodelofclostridioidesdifficilecolitis
AT natalietengberg novelprobiotictherapeuticinamurinemodelofclostridioidesdifficilecolitis
AT jasonnavarro novelprobiotictherapeuticinamurinemodelofclostridioidesdifficilecolitis
AT miriamconces novelprobiotictherapeuticinamurinemodelofclostridioidesdifficilecolitis
AT michaeltbailey novelprobiotictherapeuticinamurinemodelofclostridioidesdifficilecolitis
AT stevendgoodman novelprobiotictherapeuticinamurinemodelofclostridioidesdifficilecolitis
AT gailebesner novelprobiotictherapeuticinamurinemodelofclostridioidesdifficilecolitis
_version_ 1724215679646695424